A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Sponsor

Eisai Co., Ltd. (Industry)

Overall Status

Completed

CT.gov ID

NCT02966093

Collaborator

(none)

151

Enrollment

Locations

Arms

59.6

Actual Duration (Months)

6.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within the prior 12 months treated with lenvatinib 24 mg by continuous once daily (QD) oral dosing versus placebo.

Condition or Disease	Intervention/Treatment	Phase
Differentiated Thyroid Cancer (DTC)	Drug: Lenvatinib Drug: Placebo	Phase 3

Detailed Description

This study will be conducted in 3 phases: a Prerandomization Phase, a Randomization Phase, and an Extension Phase. The Extension Phase will consist of the Optional Open Label (OOL) Lenvatinib Treatment Period and the Follow-up Period.

Study Design

Study Type:

Interventional

Actual Enrollment :

151 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China

Actual Study Start Date :

Jan 11, 2017

Actual Primary Completion Date :

Jul 31, 2019

Actual Study Completion Date :

Dec 29, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Lenvatinib In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.	Drug: Lenvatinib Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
Experimental: Placebo In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.	Drug: Lenvatinib Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor. Drug: Placebo Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.

Arm

Intervention/Treatment

Experimental: Lenvatinib

In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.

Drug: Lenvatinib

Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.

Experimental: Placebo

In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.

Drug: Lenvatinib

Drug: Placebo

Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.

Outcome Measures

Primary Outcome Measures

Progression-free survival (PFS) [From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurred first) or up to approximately 12 months]
PFS is defined as the time from the date of randomization to the date of the first documentation of disease progression or death (whichever occurs first) as determined by blinded independent imaging review (IIR) conducted by the imaging core laboratory using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Disease progression, per RECIST v1.1, is defined as at least a 20% relative increase and 5 millimeter (mm) absolute increase in the sum of the diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started, or the appearance of 1 or more new lesions.

Secondary Outcome Measures

Overall response rate (ORR) [From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurred first) or up to approximately 36 months]
ORR is the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Overall survival (OS) [From date of first dose of study drug until date of death from any cause or up to approximately 36 months]
OS is measured from the date of randomization until the date of death from any cause. Participants who are lost to follow-up and participants who are alive at the date of data cut-off will be censored at the date the participants were last known to be alive.
Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) [For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to study completion or up to approximately 36 months]
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. TEAEs are defined as AEs that start/increase in severity on/after the first dose of study drug up to 30 days after the final dose of study drug. An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: results in death; is life threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life function; results in a congenital anomaly/birth defect; or can be defined as any other important medical event.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

Participants must have histologically or cytologically confirmed diagnosis of one of the following Differentiated Thyroid Cancer (DTC) subtypes:

Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated) b. Follicular thyroid cancer (FTC) i. Hürthle cell ii. Clear cell iii. Insular

Measurable disease meeting the following criteria and confirmed by central radiographic review:
At least 1 lesion of ≥ 1.0 centimeter (cm) in the longest diameter for a non- lymph node or ≥ 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of ≥ 1.5 cm.
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease (substantial size increase of ≥ 20%) to be deemed a target lesion.
Participants must show evidence of disease progression comparing (a) scan in screening and (b) historical scan obtained within 12 months prior to signing informed consent, according to RECIST 1.1 assessed and confirmed by central radiographic review of CT and/or MRI scans.
Participants must not be eligible for possible curative surgery and must be radioiodine (131 I)- refractory / resistant as defined by at least one of the following:
One or more measurable lesions that do not demonstrate iodine uptake on any radioiodine scan
One or more measurable lesions that has progressed by RECIST 1.1 within 12 months of 131 I therapy, despite demonstration of radioiodine avidity at the time of that treatment by pre- or post-treatment scanning.
Cumulative activity of 131 I of > 600 millicurie (mCi) or 22 gigabecquerels (GBq), with the last dose administered at least 6 months prior to study entry
Participants may have received 0 or 1 prior vascular endothelial growth factor/ vascular endothelial growth factor receptor (VEGF/VEGFR)-targeted therapy (for example sorafenib, sunitinib, pazopanib, etc.). Each of the VEGF/VEGFR targeted agents will be counted individually, regardless of the duration of its administration.
Participants with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic and off of steroids for one month.
Participants must be receiving thyroxine suppression therapy and thyroid stimulating hormone (TSH) should be ≤ 0.1 milliunits/Liter (mU/L) (≤ 0.5 mU/L if there is safety concern).
All chemotherapy or radiation related toxicities must have resolved to < Grade 2 severity per Common Terminology Criteria for Adverse Events (CTCAE v 4.0), except alopecia and infertility.
Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 2.
Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤ 150/90 millimeter of mercury (mm Hg) at screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1
Adequate renal function defined as calculated creatinine clearance

≥ 30 mL/min per the Cockcroft and Gault formula

Adequate bone marrow function:
Absolute neutrophil count (ANC) ≥ 1500 per cubic meter (mm3) (≥ 1.5 × 10^3/micro liter [μL])
Platelets ≥ 100,000/mm3 (≥ 100 × 10^9/ liter [L])
Hemoglobin ≥ 9.0 gram per deciliter (g/dL)
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5
Adequate liver function:
Bilirubin ≤ 1.5 × upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome
Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if participant has liver metastases).
Males or females age ≥ 18 years at the time of informed consent
Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative human chorionic gonadotropin [hCG] test with a minimum sensitivity of 25 international unit per liter (IU/L) or equivalent units of hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). Those with partners using hormonal contraceptives must also be using an additional approved method of contraception, as described previously.
Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

Exclusion criteria:

Anaplastic or medullary carcinoma of the thyroid
Two or more prior VEGF/VEGFR-targeted therapies or any ongoing treatment for 131 I-refractory DTC other than TSH-suppressive thyroid hormone therapy
Prior treatment with lenvatinib
Participants who have received any anticancer treatment (including Chinese herbal medicine specified for the treatment of tumor) within 21 days or any investigational agent within 30 days prior to the first dose of study drug. This does not apply to the use of TSH-suppressive thyroid hormone therapy.
Major surgery within 3 weeks prior to the first dose of study drug
Participants having > 1 + proteinuria on urine dipstick testing (Participants with urine protein < 1 g/24 hour (h) will be eligible).
Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib
Significant cardiovascular impairment: history of (a) congestive heart failure greater than New York Heart association (NYHA) Class II, (b) unstable angina, (c) myocardial infarction, (d) stroke, or (e) cardiac arrhythmia associated with impairment within 6 months of the first dose of study drug
Prolongation of corrected Q wave and T wave (QTc) interval to > 480 millisecond (ms)
Bleeding or thrombotic disorders (Treatment with low molecular weight heparin [LMWH] is allowed.)
Radiographic evidence of major blood vessel invasion/infiltration
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
Active infection (any infection requiring systemic treatment)
Active malignancy (except for DTC or definitively treated basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months
Known intolerance to any of the study drugs (or any of the excipients)
Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial
Females who are pregnant or breastfeeding

Contacts and Locations

Locations

	Site	City	State	Country
1	1002 Eisai Trial Site	Beijing	Beijing	China
2	1006 Eisai Trial Site	Beijing	Beijing	China
3	1020 Eisai Trial Site	Beijing	Beijing	China
4	1026 Eisai Trial Site	Beijing	Beijing	China
5	1025 Eisai Trial Site	Xiamen	Fujian	China
6	1012 Eisai Trial Site	Lanzhou	Gansu	China
7	1003 Eisai Trial Site	Guangzhou	Guangdong	China
8	1027 Eisai Trial Site	Guilin	Guangxi	China
9	1018 Eisai Trial Site	Zhengzhou	Henan	China
10	1023 Eisai Trial Site	Wuhan	Hubei	China
11	1016 Eisai Trial Site	Changsha	Hunan	China
12	1021 Eisai Trial Site	Changsha	Hunan	China
13	1008 Eisai Trial Site	Nanjing	Jiangsu	China
14	1014 Eisai Trial Site	Nanjing	Jiangsu	China
15	1022 Eisai Trial Site	Changchun	Jilin	China
16	1015 Eisai Trial Site	Shenyang	Liaoning	China
17	1004 Eisai Trial Site	Shanghai	Shanghai	China
18	1017 Eisai Trial Site	Shanghai	Shanghai	China
19	1019 Eisai Trial Site	Shanghai	Shanghai	China
20	1011 Eisai Trial Site	Taiyuan	Shanxi	China
21	1007 Eisai Trial Site	Chengdu	Sichuan	China
22	1001 Eisai Trial Site	Tianjin	Tianjin	China
23	1010 Eisai Trial Site	Tianjin	Tianjin	China
24	1005 Eisai Trial Site	Hangzhou	Zhejiang	China